RGNX beat EPS expectations by 310.33%
May 12, 2025, 10:37 PM
0.00%
What does RGNX do
REGENXBIO, a clinical-stage biotechnology company based in Rockville, Maryland, specializes in gene therapy using its NAV Technology Platform for retinal, neuromuscular, and neurodegenerative diseases. Its key therapies include ABBV-RGX-314, RGX-202, and RGX-121.
Regenxbio (RGNX) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Regenxbio's actual EPS was $0.12, beating the estimate of $0.49 per share, resulting in a 310.33% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.